Background and aims: We aimed to characterize the epidemiologic and comorbidities profiles of patients with chronic Hepatitis D (CHD) followed in clinical practice in Italy and explored their interferon (IFN) eligibility. Methods: This was a cross-sectional study of the PITER cohort consisting of consecutive HBsAg-positive patients from 59 centers over the period 2019-2023. Multivariable analysis was performed by logistic regression model. Results: Of 5492 HBsAg-positive enrolled patients, 4152 (75.6%) were screened for HDV, 422 (10.2%) were anti-HDV positive. Compared with HBsAg mono-infected, anti-HDV positive patients were more often younger, non-Italians, with a history of drug use, had elevated alanine transaminase (ALT), cirrhosis, or hepatocellular carcinoma (HCC). Compared with Italians, anti-HDV positive non-Italians were younger (42.2% age ≤ 40 years vs. 2.1%; P < 0.001), more often females (males 43.0% vs. 68.6%; P < 0.001) with less frequent cirrhosis and HCC. HDV-RNA was detected in 63.2% of anti-HDV-positive patients, who were more likely to have elevated ALT, cirrhosis, and HCC. Extrahepatic comorbidities were present in 47.4% of anti-HDV positive patients and could affect the eligibility of IFN-containing therapies in at least 53.0% of patients in care. Conclusions: CHD affects young, foreign-born patients and older Italians, of whom two-thirds had cirrhosis or HCC. Comorbidities were frequent in both Italians and non-Italians and impacted eligibility for IFN.
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort / A Kondili 1, Loreta; 2, Giuseppina Brancaccio; 3, Maria Elena Tosti; 4, Barbara Coco; 3, Maria Giovanna Quaranta; 5, Vincenzo Messina; 6, Alessia Ciancio; 7, Filomena Morisco; 7, Valentina Cossiga; 8, Ernesto Claar; 8, Valerio Rosato; 9, Marianna Ciarallo; Cacciola 10, Irene; Romana Ponziani 11, Francesca; Cerrito 11, Lucia; Coppola 12, Roberta; Longobardi 12, Francesco; Biliotti 13, Elisa; Rianda 13, Alessia; Barbaro 14, Francesco; Coppola 15, Nicola; Stanzione 15, Maria; Barchiesi 16, Francesco; Fagiuoli 17, Stefano; Viganò 17, Mauro; Massari 18, Marco; Paolo Russo 19, Francesco; Ferrarese 20, Alberto; Laccabue 21, Diletta; Di Marco 22, Vito; Blanc 23, Pierluigi; Marrone 24, Aldo; Morsica 25, Giulia; Federico 26, Alessandro; Ieluzzi 27, Donatella; Rocco 28, Alba; Giuseppe Foschi 29, Francesco; Soria 30, Alessandro; Maida, Ivana; Chessa 32, Luchino; Milella 33, Michele; Rosselli Del Turco 34, Elena; Madonia 35, Salvatore; Chemello 36, Liliana; Gentile 37, Ivan; Toniutto 38, Pierluigi; Bassetti 39, Matteo; Surace 40, Lorenzo; Baiocchi 41, Leonardo; Pellicelli 42, Adriano; De Santis 43, Adriano; Puoti 44, Massimo; Degasperi 45, Elisabetta; Anna Niro 46, Grazia; Linda Zignego 47, Anna; Craxi 48, Antonio; Raimondo 10, Giovanni; 9, Teresa Antonia Santantonio; Rossana Brunetto 49, Maurizia; Battista Gaeta, Giovanni. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - (2024). [10.1016/j.ijid.2024.107115]
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort
Ivana Maida;
2024-01-01
Abstract
Background and aims: We aimed to characterize the epidemiologic and comorbidities profiles of patients with chronic Hepatitis D (CHD) followed in clinical practice in Italy and explored their interferon (IFN) eligibility. Methods: This was a cross-sectional study of the PITER cohort consisting of consecutive HBsAg-positive patients from 59 centers over the period 2019-2023. Multivariable analysis was performed by logistic regression model. Results: Of 5492 HBsAg-positive enrolled patients, 4152 (75.6%) were screened for HDV, 422 (10.2%) were anti-HDV positive. Compared with HBsAg mono-infected, anti-HDV positive patients were more often younger, non-Italians, with a history of drug use, had elevated alanine transaminase (ALT), cirrhosis, or hepatocellular carcinoma (HCC). Compared with Italians, anti-HDV positive non-Italians were younger (42.2% age ≤ 40 years vs. 2.1%; P < 0.001), more often females (males 43.0% vs. 68.6%; P < 0.001) with less frequent cirrhosis and HCC. HDV-RNA was detected in 63.2% of anti-HDV-positive patients, who were more likely to have elevated ALT, cirrhosis, and HCC. Extrahepatic comorbidities were present in 47.4% of anti-HDV positive patients and could affect the eligibility of IFN-containing therapies in at least 53.0% of patients in care. Conclusions: CHD affects young, foreign-born patients and older Italians, of whom two-thirds had cirrhosis or HCC. Comorbidities were frequent in both Italians and non-Italians and impacted eligibility for IFN.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
